RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non- small cell lung cancer (NSCLC)

被引：0
|
作者：
Reuss, Joshua E.
Gandhi, Sunil G.
Spigel, David R.
Janne, Pasi A.
Paz-Ares, Luis G.
Gadgeel, Shirish M.
Patel, Jyoti D.
Passiglia, Francesco
Spira, Alexander I.
Edelman, Martin Joseph
Blumenschein, George R.
Shergill, Ardaman
Burns, Timothy F.
Bhambhani, Vijeta
Patrick, Gloria
Pachter, Jonathan A.
Denis, Louis J.
Camidge, D. Ross
机构：
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Florida Canc Specialists, Lecanto, FL USA
[3] Tennessee Oncol, Dept Thorac Med Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Univ Complutense Madrid, Univ Hosp 12 Octubre, Madrid, Spain
[6] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Univ Turin, Azienda Osped Univ San Luigi, Dept Oncol, Turin, Italy
[9] US Oncol Res, Fairfax, VA USA
[10] Fox Chase Canc Ctr, Philadelphia, PA USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[12] Univ Chicago, Sect Hematol & Oncol, Dept Med, Med Ctr, Chicago, IL USA
[13] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[14] Univ Pittsburgh, Div Hematol Oncol, Dept Med, Pittsburgh, PA USA
[15] Verastem Oncol, Needham, MA USA
[16] Verastem, Needham Hts, MA USA
[17] Verastem Inc, Needham, MA USA
[18] Univ Colorado, Div Med Oncol, Dept Med, Sch Med, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9100
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial
    Capelletto, Enrica
    Bironzo, Paolo
    Denis, Louis
    Koustenis, Andrew
    Bungaro, Maristella
    Novello, Silvia
    FUTURE ONCOLOGY, 2022, 18 (16) : 1907 - 1915
  • [2] A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Pachter, Jonathan A.
    Koustenis, Andrew G.
    Patrick, Gloria
    Denis, Louis J.
    CANCER RESEARCH, 2022, 82 (12)
  • [3] A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Reuss, Joshua E.
    Spira, Alexander I.
    Janne, Pasi A.
    Rehman, Muneeb
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)
    Camidge, D. Ross
    Pachter, Jonathan
    Koustenis, Andrew
    Patrick, Gloria
    Spigel, David R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [5] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Awad, Mark M.
    Gadgeel, Shirish M.
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
    Coma, S.
    Chowdhury, S.
    Musteanu, M.
    Stewart, A.
    Pickard, L.
    Krebs, M.
    Minchom, A.
    Banerji, U.
    Barbacid, M.
    Pachter, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1124 - S1124
  • [7] Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring KRAS G12V mutations
    John, Felix
    Ruge, Lea
    Scharpenseel, Heather
    Siemanowski, Janna
    Fassunke, Jana
    Riedel, Richard
    Michels, Sebastian Yves Friedrich
    Fischer, Rieke Nila
    Rasokat, Anna
    Schulte, Wolfgang
    Franke, Karl-Josef
    Graeven, Ullrich
    Kappes, Jutta
    Kron, Anna
    Siebolts, Udo
    Merkelbach-Bruse, Sabine
    Buettner, Reinhard
    Wolf, Juergen
    Scheffler, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
    Rodney, Simon
    Stewart, Adam R.
    Perez, Victoria Sanchez
    Morton, Cienne
    Pickard, Lisa A.
    Shakouri, Taleen
    Prout, Toby
    Parmar, Mona
    Turner, Alison J.
    Coma, Silvia
    Pachter, Jonathan
    Finneran, Laura
    Hall, Emma
    Spicer, James
    Minchom, Anna
    Banerji, Udai
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Phase II Study of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
    Gerber, David E.
    Camidge, D. R.
    Morgensztern, Daniel
    Cetnar, Jeremy
    Kelly, Ronan
    Ramalingam, Suresh S.
    Spigel, David R.
    Jeong, Woondong
    Scaglioni, Pier
    Li, Marilyn
    Keegan, Mitchell
    Horobin, Joanna
    Burns, Timothy F.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S372 - S372
  • [10] Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
    Gerber, David E.
    Camidge, D. Ross
    Morgensztern, Daniel
    Cetnar, Jeremey
    Kelly, Ronan J.
    Ramalingam, Suresh S.
    Spigel, David R.
    Jeong, Woondong
    Scaglioni, Pier P.
    Zhang, Song
    Li, Marilyn
    Weaver, David T.
    Vaikus, Louis
    Keegan, Mitchell
    Horobin, Joanna C.
    Burns, Timothy F.
    LUNG CANCER, 2020, 139 : 60 - 67
12345